Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Bevacizumab with Chemotherapy for Peritoneal Mesothelioma
NCT06543069Phase 2
Key facts
- Status
- Recruiting
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Countries
- 1
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Monoclonal Antibodies
- Conditions
- malignant peritoneal mesothelioma (MPM)
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and bevacizumab in malignant peritoneal mesothelioma (MPM), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 36 months. Started Jan 2024; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Single Arm
Sintilimab + Bevacizumab + Pemetrexed + Cisplatin
03
Who it enrols
Adult patients with pathologically confirmed unresectable malignant peritoneal mesothelioma, ECOG 0-1, and adequate organ function. Excludes patients with active autoimmune diseases, significant cardiovascular disease, or recent bleeding tendencies.
04
Endpoints
Primary
Progression-Free Survival
Secondary
Overall Survival
Objective Response Rate
Disease Control Rate
Beyond the preview
Go deeper on NCT06543069.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06543069.